Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free APLS Stock Alerts $40.37 -0.68 (-1.66%) (As of 06/7/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Apellis Pharmaceuticals Short Interest DataCurrent Short Interest12,590,000 sharesPrevious Short Interest12,390,000 sharesChange Vs. Previous Month+1.61%Dollar Volume Sold Short$527.77 millionShort Interest Ratio8.6 Days to CoverLast Record DateMay 15, 2024Outstanding Shares121,370,000 sharesPercentage of Shares Shorted10.37%Today's Trading Volume508,744 sharesAverage Trading Volume1,189,230 sharesToday's Volume Vs. Average43% Short Selling Apellis Pharmaceuticals ? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202412,590,000 shares $527.77 million +1.6%N/A8.6 $41.92 4/30/202412,390,000 shares $547.51 million +16.1%N/A8.4 $44.19 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30The #1 Crypto for AI (Ad)We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75 8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51 8/15/20227,990,000 shares $548.43 million -18.8%N/A7.4 $68.64 7/31/20229,840,000 shares $553.80 million +5.0%N/A8.8 $56.28 7/15/20229,370,000 shares $431.68 million -4.4%N/A8.8 $46.07 6/30/20229,800,000 shares $443.16 million +7.1%N/A9.9 $45.22 6/15/20229,150,000 shares $376.71 million +2.0%N/A8.1 $41.17 5/31/20228,970,000 shares $371.81 million -2.0%N/A7.5 $41.45 5/15/20229,150,000 shares $360.97 million +3.7%N/A7.5 $39.45 4/30/20228,820,000 shares $383.93 million +12.4%N/A7.7 $43.53 4/15/20227,850,000 shares $414.56 million +7.7%N/A6.8 $52.81 3/31/20227,290,000 shares $370.40 million +14.1%N/A6.3 $50.81 3/15/20226,390,000 shares $255.92 million -7.0%8.0%6.8 $40.05 2/28/20226,870,000 shares $292.18 million -1.3%8.5%8.1 $42.53 2/15/20226,960,000 shares $327.61 million -4.7%8.8%8.2 $47.07 1/31/20227,300,000 shares $293.97 million +17.0%9.3%6.8 $40.27 1/15/20226,240,000 shares $251.85 million -6.7%7.9%5.9 $40.36 12/31/20216,690,000 shares $316.30 million -7.3%8.5%6.5 $47.28 12/15/20217,220,000 shares $320.06 million +9.1%9.2%6.3 $44.33 11/30/20216,620,000 shares $278.57 million +12.4%8.6%3.7 $42.08 11/15/20215,890,000 shares $247.85 million -1.0%7.6%3.2 $42.08 10/29/20215,950,000 shares $182.90 million +4.0%8.6%3.6 $30.74 10/15/20215,720,000 shares $198.08 million -10.2%8.3%3.6 $34.63 9/30/20216,370,000 shares $209.96 million +11.4%9.2%4 $32.96 9/15/20215,720,000 shares $194.02 million +10.6%8.3%3.7 $33.92 8/31/20215,170,000 shares $340.44 million +2.4%7.6%5.8 $65.85 8/13/20215,050,000 shares $290.17 million +2.9%7.5%6.4 $57.46 7/30/20214,910,000 shares $314.19 million -21.2%7.9%5.6 $63.99 7/15/20216,230,000 shares $390.18 million +4.9%10.0%7.1 $62.63 6/30/20215,940,000 shares $375.41 million -0.5%9.5%7 $63.20 6/15/20215,970,000 shares $362.08 million +6.4%9.6%7.7 $60.65 5/28/20215,610,000 shares $315.73 million -18.7%9.0%7.2 $56.28 5/14/20216,900,000 shares $314.92 million -10.6%11.0%8.9 $45.64 4/30/20217,720,000 shares $372.41 million -4.0%N/A12.1 $48.24 4/15/20218,040,000 shares $357.62 million +4.6%N/A12.4 $44.48 3/31/20217,690,000 shares $323.36 million +9.2%N/A11.7 $42.05 3/15/20217,040,000 shares $328.49 million -13.2%N/A10.7 $46.66 2/26/20218,110,000 shares $365.36 million +4.7%12.8%11.8 $45.05 2/12/20217,750,000 shares $366.73 million +1.2%12.4%11 $47.32 1/29/20217,660,000 shares $343.93 million -14.3%12.4%10.6 $44.90 1/15/20218,940,000 shares $479.18 million -1.1%15.1%12.5 $53.60 12/31/20209,040,000 shares $516.46 million +7.1%15.3%13.4 $57.13 12/15/20208,440,000 shares $439.30 million -6.6%14.3%12.3 $52.05 11/30/20209,040,000 shares $426.87 million -9.1%15.3%14.6 $47.22 11/15/20209,940,000 shares $384.98 million -2.5%16.8%16.7 $38.73 10/30/202010,190,000 shares $331.79 million -4.2%17.2%18.1 $32.56 10/15/202010,640,000 shares $376.87 million -2.4%18.0%18.6 $35.42 9/30/202010,900,000 shares $328.85 million +3.8%18.5%16.8 $30.17 9/15/202010,500,000 shares $327.60 million +1.9%17.8%15.5 $31.20 8/31/202010,300,000 shares $317.55 million +0.9%17.5%14 $30.83RSVP: Charles Payne’s Cash Flow Workshop (Ad)Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? It's true.Click here to register for free. 8/14/202010,210,000 shares $289.76 million +0.7%17.3%13 $28.38 7/31/202010,140,000 shares $262.52 million +0.8%17.2%12 $25.89 7/15/202010,060,000 shares $321.01 million +4.4%17.1%10.9 $31.91 6/30/20209,640,000 shares $314.84 million +10.2%16.4%10.1 $32.66 6/15/20208,750,000 shares $285.16 million +7.2%14.9%9.1 $32.59 5/29/20208,160,000 shares $277.93 million +11.6%13.9%7.8 $34.06 5/15/20207,310,000 shares $226.61 million +20.2%12.4%6.9 $31.00 4/30/20206,080,000 shares $208.36 million +7.8%10.5%5.9 $34.27 4/15/20205,640,000 shares $180.37 million -1.2%9.7%5.9 $31.98 3/31/20205,710,000 shares $210.53 million -2.0%9.9%3.8 $36.87 3/13/20205,825,200 shares $163.98 million -9.6%18.3%5.6 $28.15 2/28/20206,440,000 shares $153.92 million +4.0%20.3%4.5 $23.90 2/14/20206,190,000 shares $191.58 million -7.2%11.1%4.3 $30.95 1/31/20206,670,000 shares $229.71 million No Change12.6%4.7 $34.44 1/15/20206,670,000 shares $289.28 million +22.4%12.6%4.9 $43.37 12/31/20195,450,000 shares $225.09 million +2.3%10.2%4.1 $41.30 8/15/20192,398,100 shares $68.66 million -6.6%7.6%6.1 $28.63 APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 12,590,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 9.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: Walleye Trading LLC, Ikarian Capital LLC, Jane Street Group LLC, PEAK6 Investments LLC, SG Americas Securities LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 12,590,000 shares, an increase of 1.6% from the previous total of 12,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Apellis Pharmaceuticals: ALX Oncology Holdings Inc. (11.56%), Omeros Co. (24.44%), Rigel Pharmaceuticals, Inc. (3.22%), Seres Therapeutics, Inc. (15.01%), Genmab A/S (0.45%), Alnylam Pharmaceuticals, Inc. (2.01%), Teva Pharmaceutical Industries Limited (1.16%), Royalty Pharma plc (3.47%), BioMarin Pharmaceutical Inc. (1.97%), BeiGene, Ltd. (1.75%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading down $0.68 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ALXO Short Interest Data OMER Short Interest Data RIGL Short Interest Data MCRB Short Interest Data GMAB Short Interest Data ALNY Short Interest Data TEVA Short Interest Data RPRX Short Interest Data BMRN Short Interest Data BGNE Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.